June 30, 2020 -- Hoth Therapeutics has inked a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential peptide COVID-19 treatment.
Under the direction of Michael Peters, PhD, VCU researchers will develop and optimize peptide biomimetics to achieve high binding rates to the receptor-binding domain of the SARS-CoV-2 spike protein at the nanomolar level, with demonstrated negligible toxicity, according to Hoth. They will conduct point mutations in silico in an effort to improve the stability and binding properties of these decoy peptides, the company said.
Next, these optimized, in silico peptides will be synthesized and experimentally characterized through structure determination, binding to the spike protein, and cell challenge assays with SARS-CoV-2, according to the firm. Hoth has secured exclusive license to this peptide COVID-19 therapeutic.
Copyright © 2020 scienceboard.net